CNCR vs. IDNA

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.47%/yr for IDNA.

Performance

CNCR vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

IDNA

• 1D: -2.18%
• 1M: -2.18%
• YTD: 9.51%
• 6M: 10.53%
• 1Y: 41.74%
• 3Y*: 6.48%
• 5Y*: -8.26%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. IDNA - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	-1.10%

CNCR vs. IDNA - Sectors Allocation Comparison

Sectors	CNCR	IDNA
Healthcare	96.6%	97.8%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	0.4%
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDNA

IDNA Risk / Return Rank: 57
IDNA Sharpe Ratio Rank: 49
IDNA Sortino Ratio Rank: 50
IDNA Omega Ratio Rank: 43
IDNA Calmar Ratio Rank: 79
IDNA Martin Ratio Rank: 64

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	IDNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.71	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.10	—

Drawdowns

CNCR vs. IDNA - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for CNCR and IDNA.

Drawdown Indicators

	CNCR	IDNA	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-68.26%	+68.26%
Max Drawdown (1Y) Largest decline over 1 year	—	-10.66%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-29.73%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-68.26%	—
Current Drawdown Current decline from peak	0.00%	-46.01%	+46.01%
Average Drawdown Average peak-to-trough decline	0.00%	-36.24%	+36.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.70%	—

Volatility

Volatility by Period

	CNCR	IDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.24%	—
Volatility (6M) Calculated over the trailing 6-month period	—	18.21%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	24.51%	-24.51%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	28.42%	-28.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	29.53%	-29.53%

CNCR vs. IDNA - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than IDNA's 0.47% expense ratio.

Dividends

CNCR vs. IDNA - Dividend Comparison

CNCR has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 1.08%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	1.08%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Frequently Asked Questions

Which ETF is better, CNCR or IDNA?

On fees, IDNA is cheaper at 0.47% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or IDNA?

IDNA is cheaper with a 0.47% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or IDNA?

IDNA has the higher dividend yield at 1.08%, compared with 0.00% for CNCR.

What is the main difference between CNCR and IDNA?

CNCR tracks Loncar Cancer Immunotherapy Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: Exchange Traded Concepts and iShares. Their fees differ too: 0.79% for CNCR and 0.47% for IDNA.